Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy? - Wikidata - awgldk - TriplyDB

Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?

Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?

http://www.wikidata.org/entity/Q35076216

about

Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.

P2860

Q37794991-387E0C17-37AC-49BD-AD41-D1EFC693691A Q49344279-6726B537-36F2-43FB-B592-EEC7EE6D4E15

P2860

Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?

http://www.wikidata.org/entity/Q35076216

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Adjuvant bisphosphonates in en ...... hat is their place in therapy?

@ast

Adjuvant bisphosphonates in en ...... hat is their place in therapy?

@en

type

label

Adjuvant bisphosphonates in en ...... hat is their place in therapy?

@ast

Adjuvant bisphosphonates in en ...... hat is their place in therapy?

@en

prefLabel

Adjuvant bisphosphonates in en ...... hat is their place in therapy?

@ast

Adjuvant bisphosphonates in en ...... hat is their place in therapy?

@en

P1433

Q35076216-5378225D-F949-4B75-9D03-DA54381A9C35

P1476

Q35076216-C3F355B0-84D9-4A41-B936-6CA568E3C1E2

P2093

Q35076216-04BCDA2C-2026-4C50-8E41-F04F8FB10A59

Q35076216-0D58B4E3-A55E-4147-BCA0-66E5B0F7986C

Q35076216-1F79B6E2-F44E-4B7D-B67F-728898641226

Q35076216-2BD6B30C-0821-4F88-905E-C9FFB0637804

Q35076216-550DB6FF-A15C-4964-93D9-E1AD9ACAD759

Q35076216-60E94803-EF07-4C0D-8E0C-EAAFEDAC6F59

Q35076216-7D1D52EB-EC73-4AC8-BFFB-CB0141B57B14

Q35076216-ADE4858A-285F-4D52-9D01-20CAA046BFE4

Q35076216-BE7C6A74-D53D-4152-88F6-6CE732E9CE12

Q35076216-C3B2DA97-92C7-449E-90B6-B28F6060C3A7

P2860

Q35076216-04AD7BAD-FD31-4109-9BDB-3031701D5888

Q35076216-04B2A937-DA9D-4C0E-A9DD-5E2AF4840278

Q35076216-05540DB4-B2BD-4F46-8508-A9BAFB50D338

Q35076216-15CEA756-8662-4BA0-860B-A42BAC461AFE

Q35076216-1D5630E4-62B8-4FB7-A82F-7500A335D42D

Q35076216-1FF4555C-CE38-4577-81DB-3AC17F70E5E9

Q35076216-2ED184BE-04F2-48AA-8BAB-D70DB4E6562E

Q35076216-39A7DD35-8251-4D28-9D92-B92710020DD3

Q35076216-3C9ECE2B-AB0A-4FD5-AF85-2C296D926E05

Q35076216-3CAE2C0E-EA8F-4221-A4FB-19ABB791E12F

P304

Q35076216-79CC6750-2993-404B-9368-83694B487596

P31

Q35076216-E8DD3D1D-51B4-4BFE-AE9C-BEF33469114F

P356

Q35076216-11606B09-C7C1-4EB1-8F0B-C74E9CC4D1B6

P433

Q35076216-A1F20CA3-D6E9-4EBA-BD66-78641D24CEED

P478

Q35076216-1902063F-8202-4D93-85C3-0E7C4F1DFFDF

P577

Q35076216-746324E6-29FE-4C76-A12E-90ECD961FC28

P5875

Q35076216-14CE31E3-0BAD-4728-BDF4-542135B899FD

P698

Q35076216-F0812C69-A635-4A44-A0BC-F7B2D88C4715

P932

Q35076216-5720698D-47B4-4FF8-837F-689E1EA24677

P356

1758834009344594

P1433

Therapeutic advances in medical oncology

P1476

Adjuvant bisphosphonates in en ...... hat is their place in therapy?

@en

P2093

Andrea Dal Borgo

http://www.w3.org/2001/XMLSchema#string

Emanuel Sporn

http://www.w3.org/2001/XMLSchema#string

Florian Fitzal

http://www.w3.org/2001/XMLSchema#string

Guenther Steger

http://www.w3.org/2001/XMLSchema#string

Michael Gnant

http://www.w3.org/2001/XMLSchema#string

Peter Blaha

http://www.w3.org/2001/XMLSchema#string

Peter Dubsky

http://www.w3.org/2001/XMLSchema#string

Peter Panhofer

http://www.w3.org/2001/XMLSchema#string

Raimund Jakesz

http://www.w3.org/2001/XMLSchema#string

Ruth Exner

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Osteoclast differentiation and activation

Metastasis to bone: causes, consequences and therapeutic opportunities

The distribution of secondary growths in cancer of the breast. 1889

Aromatase and its inhibitors.

Cellular and molecular mechanisms of action of bisphosphonates.

Changes in bone mineral density with age in men and women: a longitudinal study.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

P304

123-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834009344594

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51521157

http://www.w3.org/2001/XMLSchema#string

P698

21789117

http://www.w3.org/2001/XMLSchema#string

P932

3126000

http://www.w3.org/2001/XMLSchema#string